<DOC>
	<DOC>NCT02024308</DOC>
	<brief_summary>The purpose of the study is to determine whether Fludarabine in combination with cytarabine is more effective than high-dose cytarabine in post-remission therapy for patients with AML1-ETO acute myeloid leukemia.</brief_summary>
	<brief_title>AML1-ETO Acute Myeloid Leukemia With Fludarabine and Cytarabine Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myeloid, Acute</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Clinical and laboratory diagnosis of AML1ETO positive acute myeloid leukemia In status of complete remission after one to two courses of induction therapy with DA(Daunorubicin 60mg/m2/d for 3 days, cytarabine 100mg/m2/d for 57days) regimen ECOG (Eastern Cooperative Oncology Group) score: &lt;2 Serious liver/ kidney dysfunction Cardiac function level: 2 above Female in pregnancy or lactation With serious infection diseases or other diseases</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>acute myeloid leukemia,</keyword>
	<keyword>AML1-ETO fusion protein,</keyword>
	<keyword>Fludarabine,</keyword>
	<keyword>recurrence</keyword>
</DOC>